idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instanz:
Teilen: 
02.12.2022 10:43

Optimal blood tests for development of new therapies of Alzheimer’s disease

Press Contact at University of Gothenburg: Margareta G. Kubista, phone +46 705 30 19 80, press@sahlgrenska.gu.se Kommunikationsavdelningen / Communications Department
Schwedischer Forschungsrat - The Swedish Research Council

    A new study have identified which blood tests are best at detecting Alzheimer’s disease during the earliest stages, and also other another blood test that are is optimal for detecting relevant treatment effects. These findings will speed up the development of new therapies that can slow down the disease progression.

    The Swedish study lead by Professor Oskar Hanssson, Lund University, and Professor Kaj Blennow, University of Gothenburg, looked at several newly development blood tests for Alzheimer’s disease pathology and neurodegeneration in 575 individuals from the BioFINDER cohort. In 242 participants, the plasma tests were repeated for up to 6 years, along with cognitive testing and magnetic resonance imaging.

    The study, published in Nature Medicine, revealed that multiple blood biomarkers, namely phospho-tau231 and Aβ42/40, were sufficient in identifying Alzheimer’s disease pathology, even in participants with no symptoms and thus, could be used as strategy to select the correct individuals for novel disease modifying trials – a task which currently requires expensive molecular imaging technique or lumbar punctures.

    Yet, over the 6 years tested, it was shown that only phospho-tau217 was related to Alzheimer’s disease pathology, a decline in cognitive performance and increased brain atrophy typical of incipient Alzheimer’s. Therefore, phospho-tau217 will be an ideal marker for detection of relevant disease-modifying effects of novel interventions. The study has large implications on the use of blood test in the recently reported anti-Aβ trials.

    “Distinctive blood tests may be optimal for the identification of Alzheimer’s pathology or for monitoring of disease progression and therefore have different roles in clinical trials” first author of the research study Dr. Nicholas Ashton from the University of Gothenburg explained.

    “This study has shown that phospho-tau217 is uniquely placed to be an optimal test for monitoring patients in both a clinical setting and a trial setting because of its longitudinal association with Alzheimer’s development”.

    An important aspect of this study was that p-tau217 was able to monitor such changes in pathology and cognition at very early stages of the disease process. This finding was replicated in an independent cohort from the USA, Wisconsin Registry for Alzheimer’s Prevention (WRAP).

    “Besides improving the design of clinical trials, the novel blood tests will revolutionize the diagnoses of early stages of Alzheimer’s disease”, says Oskar Hansson. “Further, phospoho-tau217 might be used in the future to monitor the response in individual patients to disease-modifying therapies in clinical practice.


    Wissenschaftliche Ansprechpartner:

    Contact:

    Nicholas Ashton, assistant professor at department of neurochemistry, University of Gothenburg, Sweden, phone +44 748 026 87 66, email nicholas.ashton@gu.se

    Kaj Blennow, professor at department of neurochemistry, University of Gothenburg, Sweden, phone +46 761 07 38 35, email kaj.blennow@neuro.gu.se

    Oskar Hansson, professor in neurology at the clinical memory research unit, Lund University, Sweden, phone +46 72 226 7745, email oskar.hansson@med.lu.se

    Image: Nicholas Ashton, Kaj Blennow and Oskar Hansson (photo: University of Gothenburg, Lund University)


    Originalpublikation:

    Title: Differential roles of plasma p-tau217, p-tau231 and Aβ42/40 for trial selection and 2 longitudinal disease monitoring in early Alzheimer’s disease,


    Weitere Informationen:

    https://www.nature.com/articles/s41591-022-02074-w
    http://www.biofinder.se
    https://www.expertsvar.se/wp-content/uploads/2022/11/Ashton-Blennow-Hansson-1-10...


    Bilder

    Merkmale dieser Pressemitteilung:
    Journalisten
    Medizin
    überregional
    Forschungsergebnisse
    Englisch


     

    Hilfe

    Die Suche / Erweiterte Suche im idw-Archiv
    Verknüpfungen

    Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.

    Klammern

    Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).

    Wortgruppen

    Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.

    Auswahlkriterien

    Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).

    Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).